sodium-bicarbonate and Back-Pain

sodium-bicarbonate has been researched along with Back-Pain* in 2 studies

Other Studies

2 other study(ies) available for sodium-bicarbonate and Back-Pain

Article	Year
Primary Sjögren's syndrome manifesting as sclerotic metabolic bone disease. BMJ case reports, 2021, Jan-11, Volume: 14, Issue:1 Primary Sjögren's syndrome (pSS) is a chronic slowly progressive autoimmune disease characterised by lymphocytic infiltration of salivary and lacrimal glands with varying degree of systemic involvement. Renal involvement, a recognised extraglandular manifestation of pSS, is commonly related to tubular dysfunction and generally manifests as distal renal tubular acidosis (RTA), proximal RTA, tubular proteinuria and nephrogenic diabetes insipidus. Untreated long-standing RTA is known to cause metabolic bone disease. Here, we present the report of a patient with sclerotic metabolic bone disease related to pSS with combined distal and proximal RTA and negative workup for other causes of sclerotic bone disease. A significant clinical and biochemical improvement, including recovery of proximal tubular dysfunction, was noted with alkali therapy. This case suggests the need to consider pSS in the diagnostic algorithm of a patient presenting with sclerotic bone disease. Topics: Absorptiometry, Photon; Acidosis, Renal Tubular; Adult; Alkaline Phosphatase; Back Pain; Bone Density; Bone Diseases, Metabolic; Female; Humans; Potassium Citrate; Radionuclide Imaging; Sjogren's Syndrome; Skeleton; Sodium Bicarbonate	2021
Severe renal toxicity due to intermediate-dose methotrexate. Cancer chemotherapy and pharmacology, 1989, Volume: 24, Issue:4 Methotrexate (MTX) is a drug widely used in the treatment of patients with malignant disease. Its well-known side effects include myelosuppression, mucositis and renal damage. These problems are primarily dose-related, tending to occur more frequently when high doses (greater than 1 g/m2) are given. We present four cases in whom severe renal and mucosal toxicity occurred with intermediate doses (200 mg/m2) of MTX despite folinic acid rescue. Possible reasons for this occurrence are discussed and means of avoiding such toxicity are suggested. Three of four patients developed severe loin pain within a few hours of injection; the significance of this symptom in relation to subsequent renal toxicity has implications for early recognition of the problem. Topics: Adult; Aged; Back Pain; Bicarbonates; Fluid Therapy; Humans; Hydrogen-Ion Concentration; Kidney Diseases; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mouth Mucosa; Mouthwashes; Sodium; Sodium Bicarbonate; Stomatitis	1989

Article

Year

Primary Sjögren's syndrome manifesting as sclerotic metabolic bone disease.

BMJ case reports, 2021, Jan-11, Volume: 14, Issue:1

Primary Sjögren's syndrome (pSS) is a chronic slowly progressive autoimmune disease characterised by lymphocytic infiltration of salivary and lacrimal glands with varying degree of systemic involvement. Renal involvement, a recognised extraglandular manifestation of pSS, is commonly related to tubular dysfunction and generally manifests as distal renal tubular acidosis (RTA), proximal RTA, tubular proteinuria and nephrogenic diabetes insipidus. Untreated long-standing RTA is known to cause metabolic bone disease. Here, we present the report of a patient with sclerotic metabolic bone disease related to pSS with combined distal and proximal RTA and negative workup for other causes of sclerotic bone disease. A significant clinical and biochemical improvement, including recovery of proximal tubular dysfunction, was noted with alkali therapy. This case suggests the need to consider pSS in the diagnostic algorithm of a patient presenting with sclerotic bone disease.

Topics: Absorptiometry, Photon; Acidosis, Renal Tubular; Adult; Alkaline Phosphatase; Back Pain; Bone Density; Bone Diseases, Metabolic; Female; Humans; Potassium Citrate; Radionuclide Imaging; Sjogren's Syndrome; Skeleton; Sodium Bicarbonate

2021

Severe renal toxicity due to intermediate-dose methotrexate.

Cancer chemotherapy and pharmacology, 1989, Volume: 24, Issue:4

Methotrexate (MTX) is a drug widely used in the treatment of patients with malignant disease. Its well-known side effects include myelosuppression, mucositis and renal damage. These problems are primarily dose-related, tending to occur more frequently when high doses (greater than 1 g/m2) are given. We present four cases in whom severe renal and mucosal toxicity occurred with intermediate doses (200 mg/m2) of MTX despite folinic acid rescue. Possible reasons for this occurrence are discussed and means of avoiding such toxicity are suggested. Three of four patients developed severe loin pain within a few hours of injection; the significance of this symptom in relation to subsequent renal toxicity has implications for early recognition of the problem.

Topics: Adult; Aged; Back Pain; Bicarbonates; Fluid Therapy; Humans; Hydrogen-Ion Concentration; Kidney Diseases; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mouth Mucosa; Mouthwashes; Sodium; Sodium Bicarbonate; Stomatitis

1989